Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Pharmacol ; 156: 78-85, 2018 10.
Article in English | MEDLINE | ID: mdl-30086287

ABSTRACT

Dipeptidyl peptidase-IV (DPP4) is a cell surface serine peptidase widely expressed in the brain. Recent studies suggest that DPP4 contributes to the development of febrile seizures (FS); however, the underlying mechanism is still unclear. Thus, we investigated the role of DPP4 in the progression of FS at the molecular and electrophysiological levels using FS models in vivo and in vitro. Herein, we found that both the mRNA and protein levels of DPP4 were upregulated in the FS model. Administration of the pharmacological DPP4 inhibitor sitagliptin suppressed the hyperthermia-induced neuronal excitability as determined via whole-cell patch-clamp recordings in vitro. Interestingly, sitagliptin administration activated the glucagon-like peptide-1 (GLP-1)/GLP-1 receptor (GLP-1R) pathway by increasing the expression of GLP-1 and GLP-1R in a rat model of FS. Moreover, administration of the GLP-1R inhibitor exendin9-39 increased seizure severity, and sitagliptin reversed the effect, as shown in the electroencephalogram (EEG) and patch-clamp results in a rat model of FS. Furthermore, the GLP-1R-mediated reduction in GABAergic transmission was enhanced by sitagliptin and DPP4 knockdown through increasing miniature inhibitory post-synaptic currents (mIPSCs) in vitro accompanied by increased synaptic release of GABA in vivo. Taken together, our results demonstrate a role of DPP4 in regulating GABAergic transmission via the GLP-1/GLP-1R pathway. These findings indicated that DPP4 may represent a novel therapeutic strategy and target for FS.


Subject(s)
Dipeptidyl Peptidase 4/metabolism , Glucagon-Like Peptide 1/physiology , Glucagon-Like Peptide-1 Receptor/physiology , Seizures, Febrile/metabolism , Animals , Dipeptidyl-Peptidase IV Inhibitors/pharmacology , Female , Gene Expression Regulation/drug effects , Hippocampus/cytology , Male , Neurturin/drug effects , Neurturin/physiology , RNA Interference , Rats , Rats, Sprague-Dawley , Signal Transduction , Sitagliptin Phosphate/pharmacology
2.
J Neurosci ; 25(20): 4917-29, 2005 May 18.
Article in English | MEDLINE | ID: mdl-15901773

ABSTRACT

Although traditionally recognized for maintaining extracellular matrix integrity during morphogenesis, the function of matrix metallo-proteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), in the mature nervous system is essentially unknown. Here, we report that TIMP-2 induces pheochromocytoma PC12 cell-cycle arrest via regulation of cell-cycle regulatory proteins, resulting in differentiation and neurite outgrowth. TIMP-2 decreases cyclins B and D expression and increases p21Cip expression. Furthermore, TIMP-2 promotes cell differentiation via activation of the cAMP/Rap1/ERK (extracellular signal-regulated kinase) pathway. Expression of dominant-negative Rap1 blocks TIMP-2-mediated neurite outgrowth. Both the cell-cycle arrest and neurite outgrowth induced by TIMP-2 was independent of MMP inhibitory activity. Consistent with the PC12 cell data, primary cultures of TIMP-2 knock-out cerebral cortical neurons exhibit significantly reduced neurite length, which is rescued by TIMP-2. These in vitro results were corroborated in vivo. TIMP-2 deletion causes a delay in neuronal differentiation, as demonstrated by the persistence of nestin-positive progenitors in the neocortical ventricular zone. The interaction of TIMP-2 with alpha3beta1 integrin in the cerebral cortex suggests that TIMP-2 promotes neuronal differentiation and maintains mitotic quiescence in an MMP-independent manner through integrin activation. The identification of molecules responsible for neuronal quiescence has significant implications for the ability of the adult brain to generate new neurons in response to injury and neurological disorders, such as Alzheimer's and Parkinson's diseases.


Subject(s)
Cell Differentiation/drug effects , Mitogen-Activated Protein Kinase Kinases/metabolism , Mitosis/drug effects , Neurons/drug effects , Signal Transduction/drug effects , Tissue Inhibitor of Metalloproteinase-2/pharmacology , Adenine/analogs & derivatives , Adenine/pharmacology , Animals , Animals, Newborn , Blotting, Northern/methods , Blotting, Western/methods , Bromodeoxyuridine/metabolism , Cell Cycle/drug effects , Cell Cycle/physiology , Cell Cycle Proteins/metabolism , Cell Differentiation/physiology , Cells, Cultured , Cerebral Cortex/cytology , Cyclic AMP/metabolism , Cyclin-Dependent Kinase 5/metabolism , Drug Interactions , Electrophoretic Mobility Shift Assay/methods , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Flow Cytometry/methods , Gene Expression Regulation/drug effects , Green Fluorescent Proteins/metabolism , Immunohistochemistry/methods , Immunoprecipitation/methods , Isoquinolines/pharmacology , Mice , Mice, Inbred C57BL , Mice, Knockout , Mitosis/physiology , Molecular Biology/methods , Nerve Growth Factor/pharmacology , Neurons/cytology , Neurturin/drug effects , Phosphotransferases/metabolism , Rats , Sulfonamides/pharmacology , Time Factors , Tissue Inhibitor of Metalloproteinase-2/deficiency , Tissue Inhibitor of Metalloproteinase-2/metabolism , Transfection/methods , rap1 GTP-Binding Proteins/metabolism , ras GTPase-Activating Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...